4//SEC Filing
Milanova Tsveta 4
Accession 0001439222-24-000012
CIK 0001439222other
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 4:19 PM ET
Size
9.1 KB
Accession
0001439222-24-000012
Insider Transaction Report
Form 4
Milanova Tsveta
Chief Commercial Officer
Transactions
- Exercise/Conversion
Performance share units
2024-01-20−5,448→ 0 total→ Common stock (5,448 underlying) - Exercise/Conversion
Common stock
2024-01-20+5,448→ 14,852 total - Sale
Common stock
2024-01-24$21.64/sh−1,618$35,014→ 13,234 total
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023.
- [F2]Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The PSUs were granted on January 3, 2023. The PSUs vest upon the achievement of a specified research milestone. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001957180
Filing Metadata
- Form type
- 4
- Filed
- Jan 23, 7:00 PM ET
- Accepted
- Jan 24, 4:19 PM ET
- Size
- 9.1 KB